BLISS GVS PHARMA share price has zoomed 4% and is presently trading at Rs 189.4.
Meanwhile, the BSE HEALTHCARE index is at 44,689.4 (up 0.2%).
Among the top gainers in the BSE HEALTHCARE index today are Natco Pharma (up 2.0%) and Biocon (up 1.7%).
Cipla (down 2.4%) and METROPOLIS HEALTHCARE (down 2.3%) are among the top losers today.
Over the last one year, BLISS GVS PHARMA has moved up from Rs 166.9 to Rs 189.4, registering a gain of Rs 22.5 (up 13.5%).
On the other hand, the BSE HEALTHCARE index has moved down from 44,953.7 to 44,689.4, registering a loss of 0.6% during the last 12 months.
The top losers among the BSE HEALTHCARE index stocks during this same period were COHANCE LIFESCIENCES (down 53.6%), POLY MEDICURE (down 37.8%) and SUN PHARMA ADV. RES. (down 29.0%).
Peak India: The Rally of the Past 5 Years was Just a Preview
The BSE Sensex is at 84,883.1 (down 0.2%).
The top losers among the BSE Sensex today are Tata Motors (down 2.0%) and Bharti Airtel (down 1.2%). The most traded stocks in the BSE Sensex are HDFC Bank and ITC.
In the meantime, NSE Nifty is at 26,133.3 (down 0.2%). Cipla and Tata Motors are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 77,965.0 to 84,883.1, registering a gain of 6,918.1 points (up 8.9%).
BLISS GVS PHARMA net profit grew 11.3% YoY to Rs 286 million for the quarter ended September 2025, compared to a profit of Rs 257 million a year ago. Net sales rose 12.3% to Rs 2,444 million during the period as against Rs 2,177 million in July-September 2024.
For the year ended March 2025, BLISS GVS PHARMA reported 10.6% increase in net profit to Rs 903 million compared to net profit of Rs 816 million during FY24. Revenue of the company grew 5.1% to Rs 8,097 million during FY25.
The current Price to earnings ratio of BLISS GVS PHARMA, based on rolling 12 month earnings, stands at 17.4.
Image source: hudiemm/www.istockphoto.com
Equitymaster requests your view! Post a comment on "BLISS GVS PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!